These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 3898747)
1. Strategy, yield and risks of controlling plasma lipids in the primary prevention of coronary heart disease. Oliver MF Adv Exp Med Biol; 1985; 183():225-40. PubMed ID: 3898747 [No Abstract] [Full Text] [Related]
6. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041 [TBL] [Abstract][Full Text] [Related]
7. [Prevention of cardiovascular diseases]. Akhmeteli MA Kardiologiia; 1982 May; 22(5):47-54. PubMed ID: 7047855 [No Abstract] [Full Text] [Related]
8. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. Manninen V; Elo MO; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P JAMA; 1988 Aug; 260(5):641-51. PubMed ID: 3164788 [TBL] [Abstract][Full Text] [Related]
9. [Prevention of arteriosclerotic heart and vascular diseases]. Siedek H Wien Med Wochenschr; 1971 Jul; 121(30):575-81. PubMed ID: 5564652 [No Abstract] [Full Text] [Related]
10. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate. Nye ER; Sutherland WH; Temple Wa N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550 [TBL] [Abstract][Full Text] [Related]
11. The Gemfibrozil Study. Manninen V Acta Med Scand Suppl; 1985; 701():83-8. PubMed ID: 3907298 [TBL] [Abstract][Full Text] [Related]
12. Nutritional & pharmacologic management of hyperlipoproteinemia. Pickering JE Angiology; 1982 Sep; 33(9):577-80. PubMed ID: 6957154 [TBL] [Abstract][Full Text] [Related]
13. Effect of clofibrate on progression of coronary disease: a prospective angiographic study in man. Cohn K; Sakai FJ; Langston MF Am Heart J; 1975 May; 89(5):591-8. PubMed ID: 1091127 [TBL] [Abstract][Full Text] [Related]
15. Primary prevention of coronary heart disease by lowering lipids: results and implications. Levy RI Am Heart J; 1985 Nov; 110(5):1116-22. PubMed ID: 3904377 [TBL] [Abstract][Full Text] [Related]
16. Cholesterol, coronaries, clofibrate and death. Oliver MF N Engl J Med; 1978 Dec; 299(24):1360-2. PubMed ID: 362204 [No Abstract] [Full Text] [Related]
17. Effect of gemfibrozil on serum lipid levels. Dahlén G; Gillnäs T; Børresen AL; Berg K; Ericson C Artery; 1980; 7(3):224-31. PubMed ID: 7008748 [TBL] [Abstract][Full Text] [Related]
18. Gemfibrozil therapy in patients with coronary heart disease. Bell H; Dittmeier G; Martinez L Mo Med; 1988 Jan; 85(1):27-30. PubMed ID: 3277032 [No Abstract] [Full Text] [Related]
19. Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis. Circulation; 1984 May; 69(5):1067A-1090A. PubMed ID: 6368042 [No Abstract] [Full Text] [Related]
20. A clofibrate controlled trial of gemfibrozil in the treatment of hyperlipidaemias. Tuomilehto J; Salonen J; Kuuisto P; Virtamo J; Manninen V; Mälkönen M Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):38-40. PubMed ID: 798195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]